- Home
- CHRS vs CFBK Comparison
CHRS vs CFBK Comparison
Compare CHRS & CFBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- CFBK
- Stock Information
- Founded
- CHRS 2010
- CFBK 1892
- Country
- CHRS United States
- CFBK United States
- Employees
- CHRS N/A
- CFBK N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- CFBK Major Banks
- Sector
- CHRS Health Care
- CFBK Finance
- Exchange
- CHRS Nasdaq
- CFBK Nasdaq
- Market Cap
- CHRS 191.3M
- CFBK 177.5M
- IPO Year
- CHRS 2014
- CFBK 1998
- Fundamental
- Price
- CHRS $1.39
- CFBK $22.85
- Analyst Decision
- CHRS Strong Buy
- CFBK
- Analyst Count
- CHRS 4
- CFBK 0
- Target Price
- CHRS $5.38
- CFBK N/A
- AVG Volume (30 Days)
- CHRS 2.0M
- CFBK 35.9K
- Earning Date
- CHRS 03-12-2025
- CFBK 02-05-2025
- Dividend Yield
- CHRS N/A
- CFBK 1.23%
- EPS Growth
- CHRS N/A
- CFBK N/A
- EPS
- CHRS N/A
- CFBK 2.04
- Revenue
- CHRS $304,340,000.00
- CFBK $44,396,000.00
- Revenue This Year
- CHRS $2.47
- CFBK N/A
- Revenue Next Year
- CHRS N/A
- CFBK N/A
- P/E Ratio
- CHRS N/A
- CFBK $11.18
- Revenue Growth
- CHRS 44.19
- CFBK N/A
- 52 Week Low
- CHRS $0.66
- CFBK $16.92
- 52 Week High
- CHRS $2.97
- CFBK $31.17
- Technical
- Relative Strength Index (RSI)
- CHRS 45.86
- CFBK 40.04
- Support Level
- CHRS $1.38
- CFBK $21.58
- Resistance Level
- CHRS $1.60
- CFBK $22.99
- Average True Range (ATR)
- CHRS 0.13
- CFBK 0.98
- MACD
- CHRS -0.03
- CFBK -0.12
- Stochastic Oscillator
- CHRS 9.52
- CFBK 33.62
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.
About CFBK CF Bankshares Inc.
CF Bankshares Inc is engaged in the provision of a variety of financial services. It provides personalized business banking products and services, including commercial loans and leases, commercial and residential real estate loans, equipment leasing, SBA loans, and treasury management depository services. The revenues are derived principally from the interest and fees on loans originated and noninterest income generated on the sale of loans.